Scientific KnowledgeLooking for development status?Clinical stage, comparable drugs/devices, and estimated availability are tracked in the Therapy Pipeline.
SPM-0404
AMPA/kainate glutamate-receptor antagonist
Evidence level
No primary evidence catalogued yet
How it works
Sea Pharmaceuticals' lead molecule, blocking AMPA and kainate glutamate receptors to reduce excessive excitatory transmission, a counter to the central hyperexcitability common to several tinnitus mechanisms, though not tied to one specific hypothesis here. Also in development for epilepsy and sporadic ALS.
This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.
Explore connections· click any item to explore
Sponsor1